Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant)

Shanghai, ChinaFEI 3015009021

Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant) is a drug establishment in Shanghai, China, registered with the US FDA under FEI 3015009021. Its registered operations are: Analytical testing, Labelling, Packaging. 1 EU/UK GMP certificate is matched to this site, 1 inspected within the last three years.

Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology

Cite as: PharmaTek, “Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant): FDA registration, inspection and GMP record (FEI 3015009021)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/boehringer-ingelheim-biopharmaceuticals-china-ltd-branch-plant-shangha-3015009021

Registered operations

Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.

Analytical testingLabellingPackaging

GMP documents matched to this site (1)

DocumentAuthorityInspectionSource
ES/048HV/26
GMP certificate
Competent authority of Spain13 Feb 2026
within 3-year review window
EudraGMDP

A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.

FDA inspection outcomes (0)

FDA has published no inspection classification for FEI 3015009021. FDA does not publish every inspection, so this is not evidence the site has not been inspected.

FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection.

What this page does not show

  • Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
  • Capacity, scale, price or current availability: no regulator publishes these.
  • The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
For suppliers

Is this Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant)?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.